Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2026
Endoscopic Type I Tympanoplasty: Comparative Outcomes of Autograft, Allograft, and Xenograft.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsai Yi-Chen, Hu Chih-Yu, Zhang Bang-Yan, Yeh Kuan-Ting, Chan Kai-Chieh
Аннотация
UNLABELLED: ImportanceTo our knowledge, this represents the first adult-only, fully endoscopic, three-arm comparative cohort of autograft, allograft, and xenograft materials in type I tympanoplasty.ObjectiveTo compare graft-take, audiometric outcomes, operative time, and complications among perichondrium, MegaDerm, and Biodesign in adult endoscopic type I tympanoplasty.
DESIGN: Retrospective comparative cohort study.
SETTING: Tertiary referral center.
PARTICIPANTS: Adults who underwent endoscopic type I tympanoplasty with perichondrium, MegaDerm or Biodesign between October 2021 and March 2025. Patients with revision surgery, concomitant otologic procedures, active middle-ear disease, profound sensorineural hearing loss, preoperative air-bone gap (ABG) ≥50 dB, or follow-up <3 months were excluded.Intervention or ExposuresEndoscopic type I tympanoplasty using perichondrium (autograft), MegaDerm (allograft), or Biodesign (xenograft).
MAIN OUTCOME MEASURES: Graft-take rate, hearing gain (air-conduction and ABG), operative time, and complications.ResultsNinety-three ears were analyzed (perichondrium n = 33; MegaDerm n = 21; Biodesign n = 39). Three-month graft-take rates were similar, and final graft-take rates remained comparable across groups (3 months: 90.9%, 90.5%, 94.9%; P = .6862; final: 84.8%, 85.7%, 84.6%; P > .999). Air-conduction (AC) and ABG improved significantly within all groups. Between-group differences were not significant for AC gain (13.79 ± 9.84 vs 7.24 ± 12.46 vs 9.14 ± 10.01 dB; P = .0804) or ABG gain (9.58 ± 10.46 vs 8.82 ± 10.37 vs 7.58 ± 8.46 dB; P = .7757); the proportion achieving postoperative ABG ≤20 dB was similar (P = .475). Operative time was significantly longer for perichondrium (98.23 ± 32.35, 68.52 ± 20.84, and 74.88 ± 17.27; P < .0001). Complications were infrequent (otomycosis, n = 3; myringitis, n = 1), and no facial palsy, intractable vertigo, profound sensorineural hearing loss(SNHL), or dysgeusia occurred.
CONCLUSION: In adult endoscopic type I tympanoplasty, perichondrium, MegaDerm, and Biodesign demonstrated comparable short-term graft-take and audiometric outcomes, while commercially available grafts were associated with shorter operative time.
RELEVANCE: These findings support patient-centered graft selection balancing donor-site considerations, operative efficiency, and cost; prospective studies with standardized follow-up and patient-reported outcomes are warranted.
DESIGN: Retrospective comparative cohort study.
SETTING: Tertiary referral center.
PARTICIPANTS: Adults who underwent endoscopic type I tympanoplasty with perichondrium, MegaDerm or Biodesign between October 2021 and March 2025. Patients with revision surgery, concomitant otologic procedures, active middle-ear disease, profound sensorineural hearing loss, preoperative air-bone gap (ABG) ≥50 dB, or follow-up <3 months were excluded.Intervention or ExposuresEndoscopic type I tympanoplasty using perichondrium (autograft), MegaDerm (allograft), or Biodesign (xenograft).
MAIN OUTCOME MEASURES: Graft-take rate, hearing gain (air-conduction and ABG), operative time, and complications.ResultsNinety-three ears were analyzed (perichondrium n = 33; MegaDerm n = 21; Biodesign n = 39). Three-month graft-take rates were similar, and final graft-take rates remained comparable across groups (3 months: 90.9%, 90.5%, 94.9%; P = .6862; final: 84.8%, 85.7%, 84.6%; P > .999). Air-conduction (AC) and ABG improved significantly within all groups. Between-group differences were not significant for AC gain (13.79 ± 9.84 vs 7.24 ± 12.46 vs 9.14 ± 10.01 dB; P = .0804) or ABG gain (9.58 ± 10.46 vs 8.82 ± 10.37 vs 7.58 ± 8.46 dB; P = .7757); the proportion achieving postoperative ABG ≤20 dB was similar (P = .475). Operative time was significantly longer for perichondrium (98.23 ± 32.35, 68.52 ± 20.84, and 74.88 ± 17.27; P < .0001). Complications were infrequent (otomycosis, n = 3; myringitis, n = 1), and no facial palsy, intractable vertigo, profound sensorineural hearing loss(SNHL), or dysgeusia occurred.
CONCLUSION: In adult endoscopic type I tympanoplasty, perichondrium, MegaDerm, and Biodesign demonstrated comparable short-term graft-take and audiometric outcomes, while commercially available grafts were associated with shorter operative time.
RELEVANCE: These findings support patient-centered graft selection balancing donor-site considerations, operative efficiency, and cost; prospective studies with standardized follow-up and patient-reported outcomes are warranted.